Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.K. Centrum Ad Review Sets High Bar For Gender-Specific Claims

This article was originally published in The Tan Sheet

Executive Summary

The U.K. Advertising Standards Agency says that while a television ad for Centrum multivitamins tailored to each gender did not make improper claims directly, the spot creates potential for consumers to believe it implies those claims.

You may also be interested in...



CSPI Expects Pfizer’s Centrum Claim Changes To Resonate Across Industry

Pfizer will discontinue advertising claims for Centrum Ultra Women’s and Silver Women’s multivitamin supplements for “breast health” and Centrum Ultra Men’s and Silver Ultra Men’s for “colon health.”

Bayer Relates Feeling ‘Sexy’ To Quick Relief For Allergies In Astepro Allergy Ad Campaign

Campaign featuring actress Meghann Fahy says "allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.” Ads launch two months after FDA granted tentative approval for two ANDAs for generic equivalents, indicating approval could come pending resolution of patent litigation.

US Infant Formula Supply Chain Strategy Delivered

FDA immediate actions include ensuring providers know they’re required to develop redundancy risk management plans, enhancing inspections of manufacturers, including by expanding and improving training for investigators, and expediting reviews of premarket submissions for new products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel